216 related articles for article (PubMed ID: 24010906)
1. Role of positron emission tomography/computed tomography in breast cancer.
Bourgeois AC; Warren LA; Chang TT; Embry S; Hudson K; Bradley YC
Radiol Clin North Am; 2013 Sep; 51(5):781-98. PubMed ID: 24010906
[TBL] [Abstract][Full Text] [Related]
2. F-18 fluorodeoxyglucose-positron emission tomography imaging for primary breast cancer and loco-regional staging.
Avril N; Adler LP
Radiol Clin North Am; 2007 Jul; 45(4):645-57, vi. PubMed ID: 17706529
[TBL] [Abstract][Full Text] [Related]
3. Positron emission tomography/computed tomography in melanoma.
Bourgeois AC; Chang TT; Fish LM; Bradley YC
Radiol Clin North Am; 2013 Sep; 51(5):865-79. PubMed ID: 24010910
[TBL] [Abstract][Full Text] [Related]
4. Clinical application of 18F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in breast cancer.
Bernsdorf M; Graff J
Clin Physiol Funct Imaging; 2014 Nov; 34(6):426-33. PubMed ID: 24267489
[TBL] [Abstract][Full Text] [Related]
5. FDG-PET/CT in the staging of local/regional metastases in breast cancer.
Robertson IJ; Hand F; Kell MR
Breast; 2011 Dec; 20(6):491-4. PubMed ID: 21807517
[TBL] [Abstract][Full Text] [Related]
6. Nuclear imaging and early breast cancer detection.
Evangelista L; Cervino AR
Curr Radiopharm; 2014; 7(1):29-35. PubMed ID: 24836945
[TBL] [Abstract][Full Text] [Related]
7. Diagnosis of recurrent and metastatic disease using f-18 fluorodeoxyglucose-positron emission tomography in breast cancer.
Eubank WB
Radiol Clin North Am; 2007 Jul; 45(4):659-67, vi. PubMed ID: 17706530
[TBL] [Abstract][Full Text] [Related]
8. ¹⁸F-Fluorodeoxyglucose positron emission tomography/computed tomography finds answers in cancer patients with increasing tumor markers and negative or equivocal conventional imaging modalities.
Salem SS; Shahin MA
Nucl Med Commun; 2012 Mar; 33(3):313-21. PubMed ID: 22237387
[TBL] [Abstract][Full Text] [Related]
9. Volume-based parameters of 18F-fluorodeoxyglucose positron emission tomography/computed tomography improve disease recurrence prediction in postmastectomy breast cancer patients with 1 to 3 positive axillary lymph nodes.
Nakajima N; Kataoka M; Sugawara Y; Ochi T; Kiyoto S; Ohsumi S; Mochizuki T
Int J Radiat Oncol Biol Phys; 2013 Nov; 87(4):738-46. PubMed ID: 24064322
[TBL] [Abstract][Full Text] [Related]
10. 18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) imaging in the staging and prognosis of inflammatory breast cancer.
Alberini JL; Lerebours F; Wartski M; Fourme E; Le Stanc E; Gontier E; Madar O; Cherel P; Pecking AP
Cancer; 2009 Nov; 115(21):5038-47. PubMed ID: 19645022
[TBL] [Abstract][Full Text] [Related]
11. PET/CT: will it change the way that we use CT in cancer imaging?
Hicks RJ; Ware RE; Lau EW
Cancer Imaging; 2006 Oct; 6(Spec No A):S52-62. PubMed ID: 17114079
[TBL] [Abstract][Full Text] [Related]
12. Standardized uptake value by positron emission tomography/computed tomography as a prognostic variable in metastatic breast cancer.
Morris PG; Ulaner GA; Eaton A; Fazio M; Jhaveri K; Patil S; Evangelista L; Park JY; Serna-Tamayo C; Howard J; Larson S; Hudis CA; McArthur HL; Jochelson MS
Cancer; 2012 Nov; 118(22):5454-62. PubMed ID: 22517371
[TBL] [Abstract][Full Text] [Related]
13. F-18 fluorodeoxyglucose positron-emission tomography in the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma: a comparison to conventional imaging.
Gallowitsch HJ; Kresnik E; Gasser J; Kumnig G; Igerc I; Mikosch P; Lind P
Invest Radiol; 2003 May; 38(5):250-6. PubMed ID: 12750613
[TBL] [Abstract][Full Text] [Related]
14. Accuracy of 18F-FDG PET/CT for primary tumor visualization and staging in T1 breast cancer.
Koolen BB; van der Leij F; Vogel WV; Rutgers EJ; Vrancken Peeters MJ; Elkhuizen PH; Valdés Olmos RA
Acta Oncol; 2014 Jan; 53(1):50-7. PubMed ID: 23672678
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic performance of fluorodeoxyglucose-positron emission tomography/computed tomography combined with ultrasonography-guided fine needle aspiration cytology for identifying axillary lymph node status in patients with breast cancer.
Machida Y; Kubota K; Katayama T; Toriihara A; Shibuya H
Eur J Surg Oncol; 2013 Jan; 39(1):26-30. PubMed ID: 23122913
[TBL] [Abstract][Full Text] [Related]
16. Positron emission tomography for the diagnosis of breast cancer.
Rosé C; Dose J; Avril N
Nucl Med Commun; 2002 Jul; 23(7):613-8. PubMed ID: 12089482
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic and prognostic application of positron emission tomography in breast imaging: emerging uses and the role of PET in monitoring treatment response.
Cintolo JA; Tchou J; Pryma DA
Breast Cancer Res Treat; 2013 Apr; 138(2):331-46. PubMed ID: 23504108
[TBL] [Abstract][Full Text] [Related]
18. Role of 2-[18F] fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in the post-therapy surveillance of breast cancer.
Chang HT; Hu C; Chiu YL; Peng NJ; Liu RS
PLoS One; 2014; 9(12):e115127. PubMed ID: 25517451
[TBL] [Abstract][Full Text] [Related]
19. Role of positron emission tomography/computed tomography in bone malignancies.
Peller PJ
Radiol Clin North Am; 2013 Sep; 51(5):845-64. PubMed ID: 24010909
[TBL] [Abstract][Full Text] [Related]
20. Detection of bone metastases in breast cancer by positron emission tomography.
Schirrmeister H
Radiol Clin North Am; 2007 Jul; 45(4):669-76, vi. PubMed ID: 17706531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
